NeuroCentrix

NeuroCentrix is an Australian healthcare and clinical research company specializing in advanced neuromodulation and pharmacological treatments for complex psychiatric and neurological conditions. The company operates specialized clinics that provide N-methyl-D-aspartate (NMDA) receptor antagonists, such as ketamine and esketamine, alongside Transcranial Magnetic Stimulation (TMS) for treatment-resistant depression and PTSD. Beyond clinical care, NeuroCentrix functions as a site for international clinical trials, partnering with global pharmaceutical companies to evaluate novel therapies in the mental health space. Their multidisciplinary approach integrates psychiatry, anesthesia, and nursing to optimize patient outcomes in cases where traditional treatments have failed. The organization is a key player in the Australian landscape for the delivery of interventional psychiatry and the study of rapid-acting antidepressants.